Edition:
United States

Astellas Pharma Inc (4503.T)

4503.T on Tokyo Stock Exchange

1,505JPY
29 Mar 2017
Change (% chg)

¥-8 (-0.53%)
Prev Close
¥1,513
Open
¥1,502
Day's High
¥1,508
Day's Low
¥1,494
Volume
6,085,000
Avg. Vol
7,587,736
52-wk High
¥1,779
52-wk Low
¥1,358

4503.T

Chart for 4503.T

About

Astellas Pharma Inc. is a Japan-based company mainly engaged in the pharmaceutical business. The Company is involved in the manufacture and sale of pharmaceutical products in Japan, the United States, Europe, China, Korea and Taiwan, through its subsidiaries. Its main products include immunosuppressive drug Prograf, overactive... (more)

Overall

Beta: 0.60
Market Cap(Mil.): ¥3,258,735.00
Shares Outstanding(Mil.): 2,153.82
Dividend: 17.00
Yield (%): 2.18

Financials

  4503.T Industry Sector
P/E (TTM): 15.45 29.37 30.15
EPS (TTM): 97.93 -- --
ROI: 14.68 13.51 13.05
ROE: 15.78 14.42 14.20

BRIEF-RIBOMIC plans joint research agreement with Astellas pharma

* Says it plans to enter into joint research agreement with Astellas pharma Inc, regarding R&D of aptamers pharmaceuticals

Mar 21 2017

BRIEF-X-Chem signs broad drug discovery collaboration with Astellas Pharma

* X-Chem Inc - announced signing of a broad drug discovery collaboration with Astellas Pharma Inc

Mar 20 2017

BRIEF-Astellas and Affinivax announce worldwide partnership for maps vaccine targeting pneumococcal disease

* Says Affinivax, Inc. and Astellas Pharma Inc. entered into an exclusive worldwide license agreement to develop and commercialize a vaccine targeting Streptococcus pneumoniae

Feb 28 2017

BRIEF-Lupin's unit Kyowa and Astellas enter into agreement

* Says Astellas and Lupin s subsidiary Kyowa enter into an agreement

Feb 27 2017

BRIEF-Astellas says to buy back up to 1.43 pct of own shares worth 50 bln yen

* to buy back up to 1.43 percent of own shares worth 50 billion yen Further company coverage:

Jan 30 2017

BRIEF-Astellas and Ironwood report positive top-line results from phase III Linaclotide trial in Japan

* Astellas and Ironwood report positive top-line results from phase III Linaclotide trial for patients with chronic constipation conducted in Japan

Jan 29 2017

Synergy wins U.S. approval for constipation drug (Jan 19)

(The Jan. 19 story corrects paragraph 9 to say Ironwood Pharma also sells Linzess in North America)

Jan 24 2017

CORRECTED-UPDATE 1-Synergy wins U.S. approval for constipation drug (Jan 19)

Jan 19 The U.S. Food and Drug Administration said on Thursday it had approved Synergy Pharmaceuticals Inc's drug to treat chronic idiopathic constipation (CIC).

Jan 24 2017

BRIEF-Astellas terminates agreement with UMN Pharma for cell culture based influenza vaccine programs

* Says co terminates agreement with UMN Pharma Inc , for the co-development and Astellas' exclusive commercialization of ASP7374 and ASP7373, the cell culture based influenza vaccine programs in Japan

Jan 10 2017

More From Around the Web

Earnings vs. Estimates